Shortage of DBL Aciclovir 250mg/10mL Intravenous infusion injection vial (AUST R: 56809)

Dear Healthcare Professional,

Shortage of DBL Aciclovir 250mg/10mL Intravenous infusion injection vial (AUST R: 56809) and alternate supply arrangement under Section 19A of the Therapeutic Goods Act 1989.

The Australian registered medicine, DBL Aciclovir 250mg/10mL Intravenous infusion injection vial (AUST R: 56809) sponsored by Pfizer Australia Pty Ltd, is in short supply due to manufacturing issues.

Pro Pharmaceuticals Group has been able to arrange supply of Aciclovir 250mg powder for solution for infusion, pack of 5 (Wockhardt, UK) as an alternative product on a temporary basis. This product is NOT registered in Australia and supply is authorised under an approval granted by the Therapeutic Goods Administration (TGA) under section 19A the Therapeutic Goods Act 1989 until 30th November 2024 

Please pass this onto your members.

We have attached the Dear Health Care Professional letter along with the Product Information and Pack Insert , please let us know if you have any questions.

For any orders please email to orders@propg.com.au or visit our website www.propg.com.au